Tag Archives | oncology new products consultant

Insights from AACR Molecular Targets Meeting

There was a lot of interesting science at the recent AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics international conference in San Francisco. In particular, the poster sessions offered the opportunity to discuss pre-clinical and early drug development work, and share insights into pathways and mechanisms of action. If you are in new product development, it’s a […]

Continue Reading

Understanding the market for PARP inhibitors

One of our areas of focus at Icarus Consultants is helping pharma, biotech clients with their commercial strategy to bring new products to market. Sally Church worked in oncology new products at Novartis and brought Gleevec to market in the United States, so has first hand experience of what it takes to make this happen. […]

Continue Reading

Zebrafish as a platform for cancer gene discovery

Icarus Consultants’ oncology new products guru, Sally Church, has published a fascinating post on Pharma Strategy Blog on how Zebrafish models of melanoma are providing new drug targets. Sally discusses recent research published in Nature that shows the histone methyltransferase SETDB1 is an oncogene that accelerates melanoma formation in co-operation with BRAF(V600E). What makes this […]

Continue Reading

AACR 2011 annual meeting in Orlando

Sally Church, PhD will be attending the American Association for Cancer Research (AACR) 2011 annual meeting in Orlando that starts this Saturday. This meeting offers insight into the next generation of PI3K, Akt and mTOR inhibitors, and which compounds have promise for future clinical development. This is Sally’s favorite meeting of the year as it […]

Continue Reading

AACR PI3-Kinase Conference Coverage #PI3K

Sally Church on Pharma Strategy Blog will be providing live coverage of the AACR PI3-Kinase conference that starts today in San Francisco. Sally AKA @MaverickNY will be live tweeting from the event that starts at 7pm (california time) today, Thursday, February 24 and runs through Sunday morning, February 27. The Cover it Live widget on […]

Continue Reading

AACR Conference on Targeting PI3K/mTOR Signaling in Cancer

Sally Church, PhD will be attending the American Association for Cancer Research (AACR) conference on the PI3K/mTOR pathway being held in San Francisco later this week, February 24-27. Meetings such as this offer insight into the next generation of PI3K, Akt and mTOR inhibitors, and which compounds have promise for future clinical development. If you […]

Continue Reading